Trial Profile

A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Enzalutamide (Primary) ; Antiandrogens
Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
Focus Therapeutic Use
Acronyms ENZADA

Most Recent Events

06 Jun 2023 Results (at data cut-off: 9 Feb 2022) reporting efficacy and safety at median follow up 42.6 months presented at the 59th Annual Meeting of the American Society of Clinical Oncology
07 Sep 2021 Status changed from recruiting to active, no longer recruiting.
14 May 2021 Planned End Date changed from 1 Mar 2027 to 1 Mar 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com